John Houston, Arvinas CEO
January 10, 2023 02:24 PM EST
R&D

Arv­inas re­ports de­lay for Pfiz­er-part­nered pro­tein degra­da­tion pro­gram

Nicole DeFeudis

Editor

Arv­inas’ stock plunged about 17% on Mon­day af­ter the com­pa­ny re­vealed an­oth­er de­lay for its Pfiz­er-part­nered pro­tein de­grad­er in com­bi­na­tion with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Will CRISPR mat­ter?

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times